“Now since then, we have seen that IOI come down. But testing continues to be robust, and we have put out the perspective that we expect our first-quarter respiratory to be around $500 million of revenue.”

In context

“expect the cost savings that we have generated there to sustain here for the long term. As we noted in previous calls, those are pretty significant. Scott Davis: Yeah. Okay. That's a good non-answer, Rainer. I get it. Understood. The flu season has been pretty nasty. God knows it's cold up here. Cold where you are at too. But are you seeing a big pickup in orders here in January? I know that you had a strong preorder season in April and such, but have you seen a pretty sizable reload as the cases have picked up? Rainer Blair: Well, we certainly in the second half of the fourth quarter saw the cases pick up quite significantly. You probably noted that the IOLI being as high as it's nearly ever been. That was manifested then also in the respiratory beat that we showed in the fourth quarter. Now since then, we have seen that IOI come down. But testing continues to be robust, and we have put out the perspective that we expect our first-quarter respiratory to be around $500 million of revenue. Scott Davis: That's helpful. Thank you, Rainer. Best of luck. Thank you. See you guys. Matt McGrew: Yep. Operator: Thank you. We will move next with Doug Schenkel with Wolfe Research. Please go ahead. Your line is open. Doug Schenkel: Good morning, Doug. Starting on bioprocessing. Given the strength of equipment growth in the fourth quarter and favorable comparisons for really at least 2026, it's a smidge surprising you didn't guide for maybe a little more growth at that line. Was there any pull forward of demand into Q4? And or is this just maybe some extra prudence as we sit here in January in what's been a tough environment and an unpredictable environment over the last few years? Matt McGrew: Yeah, Doug, maybe I'll take that. I think not too dissimilar to what we saw sort of on the co”